Lataa...
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
Adults with relapsed/refractory B-acute lymphoblastic leukemia (ALL) have a complete remission (CR) rate of 20–45% and median overall survival of 3–9 months, depending on the duration of the first remission and number of lines of salvage therapy. Allogeneic hematopoietic stem cell transplantation (a...
Tallennettuna:
| Julkaisussa: | Ther Adv Hematol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872177/ https://ncbi.nlm.nih.gov/pubmed/27247755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716640422 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|